The evolving role of direct thrombin inhibitors in acute coronary syndromes

Journal of the American College of Cardiology

Volumn 41, Issue 4 SUPPL. 4, 2003, Pages S70-S78

  Eikelboom, John ^a   White, Harvey ^b   Yusuf, Salim ^c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b GREEN LANE HOSPITAL   (New Zealand)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; EFEGATRAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; THROMBIN INHIBITOR;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DEATH; DRUG ACTIVITY; DRUG EXCRETION; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0037454047     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0735-1097(02)02687-6     Document Type: Review

References (59)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
3. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-6.
4. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999;353:1431-6.
5. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42.
6. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
7. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-52.
8. Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357-63.
9. Heras M, Chesebro JH, Penny WS, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989;79:657-65.
10. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991;78:423-34.
11. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Am Heart J 2001;141:E2-6.
12. Markwardt F. Past, present and future of hirudin. Haemostasis 1991;21:11-26.
13. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996;22:185-96.
14. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterisation of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-101.
15. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-8P.
16. McKeage K, Plosker GL. Argatroban. Drugs 2001;61:515-22.
17. Shuman RT, Rothenberger RB, Campbell CS, Smith GF, Gifford-Moore DS, Gesellchen PD. Highly selective tripeptide thrombin inhibitors. J Med Chem 1993;36:314-9.
18. Uriuda Y, Wang QD, Grip L, Ryden L, Sjoquist PO, Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed chest porcine model of coronary artery thrombosis. Cardiovasc Res 1996;32:320-7.
19. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-6.
20. Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic stable coronary artery disease: safety, half-life and effect on coagulation parameters. Circulation 1993;88:2015-22.
21. Fox KA. r-Hirudin in unstable angina pectoris: rationale and preliminary data from the APT pilot study. Eur Heart J 1995;16:28-32.
22. Zeymer U, von Essen R, Tebbe U, et al. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study: HIT-I (Hirudin for the Improvement of Thrombolysis). Eur Heart J 1995;16:22-7.
23. von Essen R, Zeymer U, Tebbe U, et al. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Coron Artery Dis 1998;9:265-72.
24. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1994;89:1557-66.
25. Molhoek GP, Laarman GJ, Lok DJ, et al. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK): interim results. Eur Heart J 1995;16:33-7.
26. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
27. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7-13.
28. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (Lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34:966-73.
29. Organisation to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769-77.
30. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
31. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
32. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Circulation 1994;90:1638-42.
33. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
34. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.
35. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-38.
36. Sharma GV, Lapsley D, Vita JA, et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993;72:1357-60.
37. Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation 1993;88:1495-501.
38. Fuchs J, Cannon CPA. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995;92:727-33.
39. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-9.
40. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-61.
41. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049-53.
42. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina: Hirulog Angioplasty study investigators. N Engl J Med 1995;333:764-9.
43. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty study. Am Heart J 2001;142:952-9.
44. Antmann E, Braunwald E. A second look at bivalirudin. Am Heart J 2001;142:929-31.
45. White HD, on behalf of the Hirulog and Early Reperfusion or Occlusion (HERO) Study Group. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63.
46. Jang I-K, Brown DF, Giugliano RP, et al. A multicentre, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999;33:1879-85.
47. Kaplinsky E. Direct antithrombin-argatroban in acute myocardial infarction (ARGAMI-2) in late breaking clinical trials. J Am Coll Cardiol 1998;32:1-7.
48. Klootwijk P, Lenderink T, Meij S, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999;20:1101-11.
49. The TRIM Investigators. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin in unstable coronary artery disease in 1209 patients: a double-blindrandomized dose-finding study. Thrombin Inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J 1997;18:1416-25.
50. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data. Lancet 2002;359:294-302.
51. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-8P.
52. Mehta S, Eikelboom JW, Natarajan M, et al. Early percutaneous coronary intervention in hirudin and unfractionated heparin-treated patients with acute coronary syndromes. Eur Heart J 2002;23:17-23.
53. Boersma E, Harrington RA, Moliterno D, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
54. Verstraete M. Modulating platelet function with direct thrombin inhibitors. Haemostasis 1996;26:70-7.
55. REPLACE Study-Angiomax in the modern PCI setting. Information available at: http://www.themedicinescompany.com/. Accessed October 4, 2002.
56. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
57. Serruys PW, Herrmann JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: HELVETICA investigators. N Engl J Med 1995;333:757-63.
58. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, on behalf of the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. N Engl J Med 2001;345:494-502.
59. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.